Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

IF 5.1 Q1 ONCOLOGY
Lung Cancer: Targets and Therapy Pub Date : 2024-06-22 eCollection Date: 2024-01-01 DOI:10.2147/LCTT.S463429
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
{"title":"Top 20 <i>EGFR+</i> NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating <i>EGFR</i> Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.","authors":"Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo","doi":"10.2147/LCTT.S463429","DOIUrl":null,"url":null,"abstract":"<p><p>The year 2024 is the 20<sup>th</sup> anniversary of the discovery of activating epidermal growth factor receptor (<i>EGFR</i>) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential \"cure\" in early-stage <i>EGFR+</i> NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most <i>EGFR+</i> NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described \"discoveries\" of activating <i>EGFR</i> mutations (del19, L858R, exon 20 insertions, and \"uncommon\" mutations) were published. To commemorate this 20<sup>th</sup> anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered \"honorable mention\" and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as \"syllabus\" for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25<sup>th</sup> anniversay of the discovery <i>EGFR</i> mutations (i.e. top 25 papers on the 25 years since the discovery of activating <i>EGFR</i> mutations).</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S463429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential "cure" in early-stage EGFR+ NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most EGFR+ NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described "discoveries" of activating EGFR mutations (del19, L858R, exon 20 insertions, and "uncommon" mutations) were published. To commemorate this 20th anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered "honorable mention" and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as "syllabus" for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25th anniversay of the discovery EGFR mutations (i.e. top 25 papers on the 25 years since the discovery of activating EGFR mutations).

表皮生长因子受体(EGFR)+ NSCLC 临床和转化科学论文 20 强,影响了表皮生长因子受体(EGFR)激活突变在 NSCLC 中发现后的 20 年。主编专家组共识调查。
2024 年是在非小细胞肺癌(NSCLC)中发现活化表皮生长因子受体(EGFR)突变的 20 周年纪念日。从那时起,基于这一发现的非小细胞肺癌治疗取得了巨大进步。其中一些研究引发了肿瘤学研究理念的巨变,并推动了 NSCLC 以外的治疗进展,使当前真正进入了针对所有实体瘤的精准肿瘤学时代。现在,我们对所有肿瘤类型甚至是 NSCLC 患者的血浆样本进行常规分子谱分析,以发现多种可操作的驱动基因突变,这与患者的临床特征无关,也不局限于晚期不治阶段。我们正越来越多地利用血浆基因分型来监测治疗反应和检测靶向治疗的耐药性。此外,我们现在正在对早期 NSCLC 进行基因分型,以便进行适当的辅助靶向治疗,从而最终可能 "治愈 "早期 EGFR+ NSCLC,这对在从不吸烟者中开展肺癌筛查具有社会意义,因为大多数 EGFR+ NSCLC 患者都从不吸烟。所有这些进展在 2004 年都是难以想象的,当时发表的五篇论文描述了 "发现 "的活化表皮生长因子受体突变(del19、L858R、20 号外显子插入和 "不常见 "突变)。为了纪念这一 20 周年纪念,我们组建了一个由全球胸部肿瘤内科专家组成的小组,以 2023 年 12 月 31 日为投票截止日期,评选出这一重大发现 20 年来的 20 篇最佳论文(发表或大会发言)。排名第 21 至 30 位的论文被视为 "荣誉奖",也会被附上注释。我们的目标是,这 30 篇论文及其影响注释,甚至所有排名靠前的论文,都将成为未来胸腔肿瘤学受训者的教育 "大纲"。最后,我们提到了可能改变实践的临床试验报告。其中一篇于2024年6月2日在线发表的LAURA论文未被列入投票论文名单,但如果在表皮生长因子受体突变发现25周年之际再次进行此次共识调查(即表皮生长因子受体激活突变发现25周年的前25篇论文),该论文必将名列前茅。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信